



# Biotech Daily

Wednesday September 19, 2018

*Daily news on ASX-listed biotechnology companies*

- \* **ASX UP, BIOTECH DOWN: REVA UP 12.5%; DIMERIX DOWN 9%**
- \* **MEDICAL DEVELOPMENTS PLAN RAISES \$7.5m OF HOPED-FOR \$5m**
- \* **RESAPP RAISES \$7.5m**
- \* **CYNATA 'MSCs RELIEVE CYTOKINE RELEASE SYNDROME' IN MICE**
- \* **PROTEOMICS, DUBLIN'S ATTUROS JOIN FORCES FOR DIAGNOSTICS**
- \* **BRAIN EXPANDS, RENAMES TECHNOLOGY 'TOTAL BRAIN'**
- \* **MEDICAL DEV CHAIR DAVID WILLIAMS INCREASES, DILUTED TO 14.5%**
- \* **BENITEC APPOINTS DR GREGORY REYES SENIOR SCIENTIFIC ADVISOR**

## MARKET REPORT

The Australian stock market was up 0.46 percent on Wednesday September 19, 2018 with the ASX200 up 28.5 points to 6,190.0 points.

Twelve of the Biotech Daily Top 40 stocks were up, 14 fell, 10 traded unchanged and four were untraded.

Reva was the best, up three cents or 12.5 percent to 27 cents with 69,121 shares traded.

ITL climbed 6.7 percent; Actinogen was up 5.9 percent; Ellex and Factor were up more than three percent; Bionomics, Mesoblast and Osprey rose more than two percent; Medical Developments, Pharmaxis and Volpara were up more than one percent; with Clinuvel, Cochlear and Resmed up by less than one percent.

Dimerix led the falls, down one cent or 9.1 percent to 10 cents, with 47,500 shares traded.

Universal Biosensors fell 4.3 percent; Impedimed was down three percent; Compumedics, Polynovo and Telix shed more than two percent; Avita, CSL, Genetic Signatures, Paradigm and Prescient were down more than one percent; with Cynata, Nanosonics, Pro Medicus and Starpharma down by less than one percent.

### MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says it has raised \$7,474,812 of a hoped-for \$5 million in a share purchase plan at \$4.00 a share.

In August, Medical Developments said it raised \$17 million in a placement at \$4.00 a share and hoped to raise a further \$5 million through a share plan (BD: Aug 8, 2018).

Today, the company said it was “delighted with the response and has decided not to scale back the applications”

Medical Developments was up five cents or 1.3 percent to \$3.85.

### RESAPP HEALTH

Resapp says it has raised \$7,500,000 at 22 cents a share through an “oversubscribed” placement to new and existing institutional and sophisticated investors.

Resapp said that the funds would be used to commercialize its Resappdx respiratory diagnostic in Europe, Australia and Asia, expand US clinical programs with a prospective adult trial and research new applications of its technology.

The company said that Morgans Corporate was the lead manager to the placement.

Resapp fell four cents or 14.8 percent to 23 cents with 14.2 million shares traded.

### CYNATA THERAPEUTICS

Cynata says its mesenchymal stem cells “significantly ameliorate the effects of cytokine release syndrome” in mice.

Cynata said that cytokine release syndrome was caused by high levels of immune system activation induced by cancer immunotherapy, resulting in symptoms including decreased or increased body temperature, nausea, headache, rash, rapid heartbeat, low blood pressure and difficulty breathing,

The company said that cytokine release syndrome was potentially life threatening.

Cynata said that intra-venous or intra-peritoneal injection of its Cymerus mesenchymal stem cells (MSCs) showed “substantial protection against [cytokine release syndrome] symptoms, with [intra-venous] administration demonstrating a generally more robust effect on cytokine reduction”.

The company said that by 24 hours after cytokine release syndrome induction, “statistically significant improvements in body temperature and clinical scores were demonstrated relative to the control animals”.

Cynata said that it would partner with companies developing cancer immunotherapies to evaluate the treatment approach in humans.

The company said the study was conducted at the University of Massachusetts Amherst and evaluated mesenchymal stem cells in a humanized model of cytokine release syndrome in mice.

Cynata head of product development Dr Kilian Kelly said that despite cancer immunotherapy being “one of the most exciting fields in medicine ... [cytokine release syndrome] is a common, unpredictable and potentially fatal complication that may limit treatment uptake”.

“These results suggest that administering a single dose of Cymerus MSCs before, during or even shortly after cancer immunotherapy treatment may provide significant therapeutic benefit and a straightforward way of limiting adverse [cytokine release syndrome] reactions,” Dr Kelly said.

Cynata fell one cent or 0.8 percent to \$1.25.

## [PROTEOMICS INTERNATIONAL LABORATORIES](#)

Proteomics says it will work with University College Dublin spin-out clinical diagnostics company Atturos to develop diagnostics in Europe.

Proteomics said that Atturos was founded to commercialize its Ocprodx blood test to diagnose whether prostate cancer was confined to the prostate.

The company said that both its Promarkerd and Ocprodx were developed using similar mass spectrometry technology platforms.

Proteomics said it had completed licencing deals for Promarkerd, which was “the world leading predictive test that gives up to four years advance warning of diabetic kidney disease in the USA and Mexico” (BD: May 28, Jun 18, Jul 17, 2018)].

The company said Europe had about 60 million diabetics, with 10.3 percent of men and 9.6 percent of women over 25 years with the condition and its prevalence was increasing, mostly due to increased weight, unhealthy diets and physical inactivity.

Proteomics said that in the developed world about one in six men were diagnosed with prostate cancer and in Europe, prostate cancer was the most common cancer for males, with more than 440,000 men newly diagnosed in 2015.

The company said that prostate cancer was the second leading cause of cancer death in American men, with 1.2 million new cases globally each year.

Proteomics managing-director Dr Richard Lipscombe said Atturos’ key technical and market knowledge aligned well with his company’s strategy to increase its footprint and develop new tests using the Promarker technology platform.

Atturos chief executive Dave Corr said that the “increasing use of proteomics in precision medicine is incredibly exciting and will have a massive impact on patient care and well-being”.

“We believe by partnering with Proteomics International in this way, these critically important tools for physicians and patients will be delivered to where they are needed sooner,” Mr Corr said.

Proteomics was untraded at 27.5 cents.

## [BRAIN RESOURCE](#)

Brain Resource says it has upgraded and expanded its brain performance and training technology platform, formerly known as Mybrainsolutions and renamed it Total Brain.

The company said that “Total Brain invites users to realize the full potential of their brain capacities, emotion, feeling, cognition and self-control, and improve their human performance at home and at work”.

Brain Resource was up 0.2 cents or 5.1 percent to 4.1 cents.

## [MEDICAL DEVELOPMENTS INTERNATIONAL](#)

Medical Developments chairman David Williams says his holding has increased but been diluted from 9,459,584 shares (15.99%) to 9,474,584 shares (14.51%).

In his substantial shareholder notice Mr Williams said he acquired 15,000 shares through the company’s share plan at \$4.00 a share on September 19, 2018.

The substantial shareholder notice said that the registered holders of the shares were Lawn Views Pty Ltd, Moggs Creek Pty Ltd and Kidder Peabody Pty Ltd.

## [BENITEC BIOPHARMA](#)

Benitec says it has appointed Dr Gregory Reyes as its senior scientific advisor, effective from today.

Benitec said that Dr Reyes had more than 30 years' research and development experience in biotechnology and pharmaceutical companies including at Pfizer and Schering-Plough and was previously Celgene Corp's head of drug discovery Biogen Idec's head of oncology research and development.

The company said that Dr Reyes held a Doctor of Medicine and Doctor of Philosophy from the Baltimore, Maryland-based Johns Hopkins School of Medicine.

Benitec was unchanged at 17 cents.